-
-
Jazz drops PTSD drug over phase 2 trial failure
-
Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data
FDA approves first genetic test to screen for opioid use disorder risks
AbbVie frees Alpine from climbing trial costs, agreeing to end study early in return for reduced fees
Philips faces Class I recall for MRI machines at risk of explosion
In The News
- Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
- UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
- Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team
Biotechnology Today
more-
Galecto posts myelofibrosis data as search for savior continues, investors shrug
Galecto is giving potential buyers and investors more data to chew over. Three months into…
Markets
more-
Weekly Market Review – March 23, 2023
Stock Markets U.S. stock markets across the board have rallied during trading the week. The…
Bio Space
moreAbbVie frees Alpine from climbing trial costs, agreeing to end study early in return for reduced fees
AbbVie has given Alpine Immune Sciences a way out of…
Philips faces Class I recall for MRI machines at risk of explosion
Philips’ latest recall has nothing to do with its hard-hit…
After DOJ indictment, SEC joins in on fraud accusations against Stimwave ex-CEO
Earlier this year, the U.S. Department of Justice arrested Laura…
Global News
moreSpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
- Galecto posts myelofibrosis data as search for savior continues, investors shrug
- Jazz drops PTSD drug over phase 2 trial failure
- Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data
- FDA approves first genetic test to screen for opioid use disorder risks
- AbbVie frees Alpine from climbing trial costs, agreeing to end study early in return for reduced fees
- Philips faces Class I recall for MRI machines at risk of explosion
- After DOJ indictment, SEC joins in on fraud accusations against Stimwave ex-CEO
- MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M
- FDA unconvinced by Clene’s request for ALS therapy’s accelerated approval tag
- Immunovant stakes claim for FcRn niche, posting midphase Graves’ data and plotting next steps